
Novo Nordisk’s $10 Billion Metsera Bid: Why Mike Doustdar Stopped Chasing the Deal
Novo Nordisk CEO Mike Doustdar pursued Pfizer's Metsera deal with an unusual two-step offer worth nearly $10 billion. The FTC raised concerns about the structure, Pfizer matched the price, and Novo…





















































